MetaCap

GSK plc ADR (GSK)

NYSE: GSKHealth CareBiotechnology: Pharmaceutical PreparationsUSD

47.76-0.06 (-0.13%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GSK stock chart

Technical analysis

Key statistics

All statistics
Market cap
$95.73B
Dividend yield
1.44% ($0.69)
Ex-dividend date
Nov 13, 2026
52-week range
45.83 – 61.70
Day range
47.70 – 48.72
Volume / Avg
2.74M / 4.03M
Beta
—

52-week range

$45.83$61.70

GSK stock today

Shares of GSK (GSK) finished lower on Nov 20 at $47.76, a drop of 0.13% or $0.06 per share, versus the S&P 500's 3.70% decline. Shares are 22.6% below their 52-week high of $61.70, set on Feb 18, 2026 and 4.2% above the 52-week low of $45.83, near the bottom of the past year's range. GSK is down 2.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.2%.

At 16.6x trailing earnings, GSK trades below the peer-group median of 33.1x. Its forward P/E of 9.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. GSK pays an annual dividend of $0.69 per share, a 1.44% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About GSK

Company profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Luke Victor Miels
Headquarters
London
Employees
66,841
IPO year
2022
Website
gsk.com

Analyst forecast

Forecast

Consensus (9 analysts)

hold

Avg. price target

$59.12+23.79%

  • Strong buy 1
  • Buy 2
  • Hold 5
  • Sell 1
  • Strong sell 0

Target range

Low $49.00High $70.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$1.48 vs $1.40
Surprise
+5.71%

Dividends

Dividend history
Annual dividend
$0.69
Last payment
$0.452
Ex-dividend date
Nov 13, 2026

GSK news

All GSK news

GSK peers

Health Care sector
GSK peer companies
CompanyPrice% ChgMarket capCompare
REGNRegeneron Pharmaceuticals Inc.920.69-0.19%$95.24Bvs GSK
SNYSanofi ADS46.52+1.00%$111.70Bvs GSK
BMYBristol-Myers Squibb Company58.80+0.79%$120.19Bvs GSK
TAKTakeda Pharmaceutical Company Limited ADR21.77+1.68%$69.55Bvs GSK
VRTXVertex Pharmaceuticals Incorporated515.02-1.08%$130.58Bvs GSK
TEVATeva Pharmaceutical Industries Limited39.23+1.79%$45.77Bvs GSK
ONCBeOne Medicines Ltd. ADR390.94-2.19%$44.66Bvs GSK
RPRXRoyalty Pharma plc Class A68.45+1.08%$39.36Bvs GSK

Indexes, lists and sector

GSK stock FAQ

What is GSK's stock price today?

GSK last traded at $47.76 as of Nov 20, 4:00 PM EST, down 0.13% on the day. Prices are delayed at least 15 minutes.

Does GSK pay a dividend?

Yes. GSK pays $0.69 per share annually, a 1.44% yield. The most recent dividend of $0.452 had an ex-dividend date of Nov 13, 2026.

What is GSK's P/E ratio?

GSK trades at a trailing P/E ratio of 16.64 and a forward P/E of 9.63, compared with a median of 33.1 for its closest peers.

Who is GSK's CEO?

Mr. Luke Victor Miels is the chief executive officer of GSK plc ADR, which has about 66,841 employees.

Has GSK ever split its stock?

Yes. The most recent GSK stock split was a 1226-for-1000 split on Jul 22, 2022, one of 5 splits on record.

What is the GSK 52-week high?

The 52-week high for GSK is $61.70 and the 52-week low is $45.83. The stock is currently 22.6% below its high.

Compare GSK